Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?
Cornelia Kunz, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany ; Silke Jörgens, Janssen-Cilag GmbH, Neuss, Germany ; Frank Bretz, Novartis AG; Nigel Stallard, The University of Warwick, Coventry, UK; Kelly Van Lancker, Ghent University, Belgium; Dong Xi, Novartis Pharmaceuticals, East Hanover, New Jersey, USA ; Sarah Zohar, Sorbonne Université, Paris, France; Christoph Gerlinger, Statistics and Data Insights, Bayer AG, Berlin, Germany ; Tim Friede, University Medical Center Göttingen, Göttingen, Germany